EMMANUEL GBALA: Open Payments
NPI 1245862648 · REISTERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$640 in 27 payments from 8 companies in 2025. Trend: 2023 $278 · 2024 $692 · 2025 $640
Food & beverage: $640
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $314 |
| Teva Pharmaceuticals USA, Inc. | 2 | $128 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
| Alkermes, Inc. | 2 | $45 |
| Tris Pharma Inc | 2 | $44 |
| Lundbeck LLC | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| TMS NeuroHealth Centers Inc. | 1 | $11 |
Products named: VRAYLAR, UZEDY, FANAPT, ARISTADA, Dyanavel XR, REXULTI, TMS NeuroHealth Centers Inc..
Industry payments across MD — which companies pay providers there.
